The site has finished its first Good Manufacturing Practice batches of drug substance and drug product, advancing its overseas production operations.

The agreement gives Fresenius exclusive access to candidates across 13 therapeutic areas, with development planned over the next decade.

The 44,500-square-meter facility will manufacture cell culture media, process liquids, and sterile sampling products for Asia-Pacific customers.

The capital project will add 160,000 liters of manufacturing capacity, increasing the total capacity by approximately 25% to nearly one million liters.

The European Medicines Agency inspection supports renewal of GMP certificate at pharmaceutical analytical testing and development site.

The expansion in Visp will now include three multiproduct suites, with commercial manufacturing capacity expected to be operational from 2028.

Haverhill’s new spray dryer, slated to become available in the last quarter of 2027, will expand solvent-based capacity for amorphous solid dispersions.

CARR’s single-use centrifugation platform will support process volumes from milliliters to more than 2,000 liters, according to the companies.